Literature DB >> 11799343

Mood changes during prednisone bursts in outpatients with asthma.

E Sherwood Brown1, Trisha Suppes, David A Khan, Thomas J Carmody.   

Abstract

Corticosteroids, such as prednisone and dexamethasone, are frequently prescribed medications sometimes associated with severe systemic side effects. Currently there are limited data regarding the psychiatric side effects of these medications, although mood changes and even psychoses have been reported. This study was designed to quantify psychiatric changes during brief courses of prednisone in patients with asthma. Outpatients with asthma (N = 32) receiving bursts of prednisone (>40 mg/day) were evaluated before, during, and after corticosteroid therapy by use of the Hamilton Rating Scale for Depression, the Young Mania Scale, the Brief Psychiatric Rating Scale, and the Internal State Scale. A Structured Clinical Interview for DSM-IV disorders was also conducted to examine past psychiatric history. Highly significant increases in the Young Mania Scale and Activation subscale of the Internal State Scale (both measures of mania) were observed with no increase in depression measures during the first 3 to 7 days of prednisone therapy. Mood changes were not correlated with improvement in airway obstruction, suggesting that mood elevations may not be in response to improvement in asthma symptoms. Subjects with past or current symptoms of depression had a significant decrease in depressive symptoms during prednisone therapy compared with those without depression. Some patients with posttraumatic stress disorder reported increases in depression and memories of the traumatic event during prednisone therapy. In summary, statistically significant changes in mood were observed even during brief courses of corticosteroids at modest dosages. The symptoms were primarily manic, not depressive. Persons with depression did not become more depressed during prednisone therapy, and, in fact, some showed improvement.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11799343     DOI: 10.1097/00004714-200202000-00009

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  26 in total

1.  Day-to-day dynamics of experience--cortisol associations in a population-based sample of older adults.

Authors:  Emma K Adam; Louise C Hawkley; Brigitte M Kudielka; John T Cacioppo
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

2.  Corticosteroid use in neuro-oncology: an update.

Authors:  Patrick Roth; Caroline Happold; Michael Weller
Journal:  Neurooncol Pract       Date:  2014-10-09

3.  Acute cognitive and behavioral effects of systemic corticosteroids in children treated for inflammatory bowel disease.

Authors:  Christine Mrakotsky; Peter W Forbes; Jane Holmes Bernstein; Richard J Grand; Athos Bousvaros; Eva Szigethy; Deborah P Waber
Journal:  J Int Neuropsychol Soc       Date:  2012-11-19       Impact factor: 2.892

4.  New-onset psychiatric disorders after corticosteroid therapy in systemic lupus erythematosus: an observational case-series study.

Authors:  Katsuji Nishimura; Masako Omori; Eri Sato; Yasuhiro Katsumata; Takahisa Gono; Yasushi Kawaguchi; Masayoshi Harigai; Hisashi Yamanaka; Jun Ishigooka
Journal:  J Neurol       Date:  2014-08-21       Impact factor: 4.849

Review 5.  Corticosteroids, immune suppression, and psychosis.

Authors:  Dana C Perantie; E Sherwood Brown
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

Review 6.  Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus.

Authors:  Samir D Bhangle; Neil Kramer; Elliot D Rosenstein
Journal:  Rheumatol Int       Date:  2013-04-16       Impact factor: 2.631

7.  Attenuation of amygdala atrophy with lamotrigine in patients receiving corticosteroid therapy.

Authors:  Shuchi Desai; Sadia Khanani; Mujeeb U Shad; E Sherwood Brown
Journal:  J Clin Psychopharmacol       Date:  2009-06       Impact factor: 3.153

8.  Asthma and Mood Disorders.

Authors:  Anupama Kewalramani; Mary E Bollinger; Teodor T Postolache
Journal:  Int J Child Health Hum Dev       Date:  2008

9.  Could chiropractors screen for adverse drug events in the community? Survey of US chiropractors.

Authors:  Monica Smith; Lisa Bero; Lynne Carber
Journal:  Chiropr Osteopat       Date:  2010-11-17

10.  A comparison of clinician-rated neuropsychological and self-rated cognitive assessments in patients with asthma and rheumatologic disorders.

Authors:  Alan B Frol; Aracely Vasquez; Yonatan Getahun; Maria Pacheco; David A Khan; E Sherwood Brown
Journal:  Allergy Asthma Proc       Date:  2013 Mar-Apr       Impact factor: 2.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.